Improvements in Signs and Symptoms of Dry Eye with MIM-D3 1% Ophthalmic Solution Compared to Placebo in Different Patient Populations
K. Meerovitch, K. Brazzell, G.W. Ousler, and G. Cumberlidge
IOVS 2015; 56: E-Abstract 4460
Safety and Efficacy of Topical Ophthalmic MIM-D3, a Novel TrkA Receptor Agonist, in a Phase 2 Clinical Trial for the Treatment of Dry Eye
G. Cumberlidge, K. Meerovitch, R. Haque and G.W. Ousler
Poster presented at the 7th International Conference on the Tear Film & Ocular Surface: Basic Science and Clinical Relevance, Taormina, Sicily, 2013
High CAE Responders Show Greater Improvement in Signs and Symptoms of Dry Eye after Treatment with MIM-D3
G. Ousler and K. Meerovitch
IOVS 2013; 54: E-Abstract 4343
Relating Improvements in Signs and Symptoms to Duration of Dry Eye Disease (DED) after Treatment with MIM-D3 Ophthalmic Solutions
K. Meerovitch, T. Lama, and D. Schaumberg
IOVS 2013; 54: E-Abstract 4340
Safety and Efficacy of MIM-D3 Ophthalmic Solutions in a Randomized, Placebo-Controlled Phase 2 Clinical Trial in Patients with Dry Eye
K. Meerovitch, G. Torkildsen, J. Lonsdale, H. Goldfarb, T. Lama, G. Cumberlidge, and G.W. Ousler
Clinical Ophthalmology 2013; 7:1275-1285
Safety and Efficacy of Topical Ophthalmic MIM-D3, a Novel TrkA Receptor Agonist, in a Phase 2 Clinical Trial for the Treatment of Dry Eye
K. Meerovitch, G. Torkildsen, J. Lonsdale, H. Goldfarb, T. Lama, G. Cumberlidge, and G.W. Ousler
IOVS 2012; 53: E-Abstract 578
An NGF Mimetic, MIM-D3, Stimulates Conjunctival Cell Glycoconjugate Secretion and Demonstrates Therapeutic Efficacy in a Rat Model of Dry Eye
P. Jain, T. Lama, R. Li, H.U. Saragovi, G. Cumberlidge, and K. Meerovitch
Experimental Eye Research 2011; 93: 503-512
Nonclinical Pharmacology, Ocular Distribution, and Safety of MIM-D3, a Novel NGF Mimetic for the Treatment of Dry Eye
K. Meerovitch, T. Lama, and G. Cumberlidge
Poster presented at the 6th International Conference on the Tear Film & Ocular Surface: Basic Science and Clinical Relevance, Florence, Italy, 2010
An NGF mimetic, MIM-D3, is a Mucin Secretagogue
K. Meerovitch, P. Jain, and T. Lama
IOVS 2009; 50: E-Abstract 4261
An NGF Mimetic, MIM-D3, Demonstrates Therapeutic Efficacy in a Rat Model of Scopolamine-induced Dry Eye
R. Li, K. Meerovitch, T. Lama, P. Jain, H.U. Saragovi, and G. Cumberlidge
IOVS 2009; 50: E-Abstract 3661
Neurotrophins Peptidomimetics Protect Retinal Pigment Epithelial (RPE) Cells Against Oxidative Stress-induced Apoptosis
P.K. Mukherjee, K. Meerovitch, T. Lama, H.U. Saragovi, and N.G. Bazan
IOVS 2009; 50: E-Abstract 2163